{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:42:31Z","timestamp":1792183351139,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Wuhan Science and Technology Major Project","award":["2021022002023425"],"award-info":[{"award-number":["2021022002023425"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00417-025-06776-y","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:59:28Z","timestamp":1740401968000},"page":"2017-2024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The rAAV2-ND1 gene therapy for Leber hereditary optic neuropathy"],"prefix":"10.1007","volume":"263","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"2","key":"6776_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF01694557","volume":"17","author":"T Leber","year":"1871","unstructured":"Leber T (1871) Ueber heredit\u00e4re und congenital-angelegte Sehnervenleiden. Albrecht Von Graefes Arch Ophthalmol 17(2):249\u2013291. https:\/\/doi.org\/10.1007\/BF01694557","journal-title":"Albrecht Von Graefes Arch Ophthalmol"},{"issue":"10","key":"6776_CR2","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1007\/s12325-018-0776-z","volume":"35","author":"A Theodorou-Kanakari","year":"2018","unstructured":"Theodorou-Kanakari A, Karampitianis S, Karageorgou V, Kampourelli E, Kapasakis E, Theodossiadis P, Chatziralli I (2018) Current and emerging treatment modalities for Leber\u2019s Hereditary Optic Neuropathy: a review of the literature. Adv Therapy 35(10):1510\u20131518. https:\/\/doi.org\/10.1007\/s12325-018-0776-z","journal-title":"Adv Therapy"},{"issue":"12","key":"6776_CR3","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1007\/s12325-019-01113-2","volume":"36","author":"C Karaarslan","year":"2019","unstructured":"Karaarslan C (2019) Leber\u2019s Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development. Adv Therapy 36(12):3299\u20133307. https:\/\/doi.org\/10.1007\/s12325-019-01113-2","journal-title":"Adv Therapy"},{"issue":"5","key":"6776_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ophtha.2019.11.014","volume":"127","author":"L Poincenot","year":"2020","unstructured":"Poincenot L, Pearson AL, Karanjia R (2020) Demographics of a large International Population of patients affected by Leber\u2019s Hereditary Optic Neuropathy. Ophthalmology 127(5):679\u2013688. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.014","journal-title":"Ophthalmology"},{"issue":"6","key":"6776_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/ICU.0000000000000212","volume":"26","author":"JH Peragallo","year":"2015","unstructured":"Peragallo JH, Newman NJ (2015) Is there treatment for Leber hereditary optic neuropathy? Curr Opin Ophthalmol 26(6):450\u2013457. https:\/\/doi.org\/10.1097\/ICU.0000000000000212","journal-title":"Curr Opin Ophthalmol"},{"issue":"11","key":"6776_CR6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4103\/ijo.IJO_358_17","volume":"65","author":"AH Manickam","year":"2017","unstructured":"Manickam AH, Michael MJ, Ramasamy S (2017) Mitochondrial genetics and therapeutic overview of Leber\u2019s hereditary optic neuropathy. Indian J Ophthalmol 65(11):1087\u20131092. https:\/\/doi.org\/10.4103\/ijo.IJO_358_17","journal-title":"Indian J Ophthalmol"},{"key":"6776_CR7","doi-asserted-by":"publisher","first-page":"21587","DOI":"10.1038\/srep21587","volume":"6","author":"X Wan","year":"2016","unstructured":"Wan X, Pei H, Zhao MJ, Yang S, Hu WK, He H, Ma SQ, Zhang G, Dong XY, Chen C, Wang DW, Li B (2016) Efficacy and safety of rAAV2-ND4 treatment for Leber\u2019s Hereditary Optic Neuropathy. Sci Rep 6:21587. https:\/\/doi.org\/10.1038\/srep21587","journal-title":"Sci Rep"},{"key":"6776_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Ma SQ, Wan X, He H, Pei H, Zhao MJ, Chen C, Wang DW, Dong XY, Yuan JJ, Li B (2016) Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy. EBioMedicine 10:258\u2013268. https:\/\/doi.org\/10.1016\/j.ebiom.2016.07.002","journal-title":"EBioMedicine"},{"issue":"4","key":"6776_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2174\/1566523218666171129204926","volume":"17","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Tian Z, Yuan J, Liu C, Liu HL, Ma SQ, Li B (2017) The Progress of Gene Therapy for Leber\u2019s Optic Hereditary Neuropathy. Curr Gene Ther 17(4):320\u2013326. https:\/\/doi.org\/10.2174\/1566523218666171129204926","journal-title":"Curr Gene Ther"},{"issue":"6","key":"6776_CR10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ceo.13515","volume":"47","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Li X, Yuan J, Tian Z, Liu H, Wang D, Li B (2019) Prognostic factors for visual acuity in patients with Leber\u2019s hereditary optic neuropathy after rAAV2-ND4 gene therapy. Clin Exp Ophthalmol 47(6):774\u2013778. https:\/\/doi.org\/10.1111\/ceo.13515","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"6776_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2174\/1566523219666190618094505","volume":"19","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Yuan JJ, Liu HL, Tian Z, Liu SW, Li B (2019) Three cases of Leber\u2019s Hereditary Optic Neuropathy with Rapid increase in Visual Acuity after Gene Therapy. Curr Gene Ther 19(2):134\u2013138. https:\/\/doi.org\/10.2174\/1566523219666190618094505","journal-title":"Curr Gene Ther"},{"issue":"8","key":"6776_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ophtha.2020.02.023","volume":"127","author":"J Yuan","year":"2020","unstructured":"Yuan J, Zhang Y, Liu H, Wang D, Du Y, Tian Z, Li X, Yang S, Pei H, Wan X, Xiao S, Song L, Xiao X, Sun J, Wang Z, Li B (2020) Seven-year follow-up of Gene Therapy for Leber\u2019s Hereditary Optic Neuropathy. Ophthalmology 127(8):1125\u20131127. https:\/\/doi.org\/10.1016\/j.ophtha.2020.02.023","journal-title":"Ophthalmology"},{"key":"6776_CR13","doi-asserted-by":"publisher","unstructured":"Johns DR, Heher KL, Miller NR, Smith KH (1993) Leber\u2019s hereditary optic neuropathy. Clinical manifestations of the 14484 mutation. Arch Ophthalmol (Chicago, Ill.: 1960) 111(4):495\u2013498. https:\/\/doi.org\/10.1001\/archopht.1993.01090040087038","DOI":"10.1001\/archopht.1993.01090040087038"},{"issue":"4","key":"6776_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/molecules27041341","volume":"27","author":"F Musiani","year":"2022","unstructured":"Musiani F, Rigobello L, Iommarini L, Carelli V, Degli Esposti M, Ghelli AM (2022) New insights on Rotenone Resistance of Complex I Induced by the m.11778G\u2009>\u2009A\/MT-ND4 mutation Associated with Leber\u2019s Hereditary Optic Neuropathy. Molecules 27(4):1341. https:\/\/doi.org\/10.3390\/molecules27041341","journal-title":"Molecules"},{"issue":"10097","key":"6776_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet (London England) 390(10097):849\u2013860. https:\/\/doi.org\/10.1016\/S0140-6736(17)31868-8","journal-title":"Lancet (London England)"},{"issue":"11","key":"6776_CR16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","volume":"124","author":"J Guy","year":"2017","unstructured":"Guy J, Feuer WJ, Davis JL, Porciatti V, Gonzalez PJ, Koilkonda RD, Yuan H, Hauswirth WW, Lam BL (2017) Gene Therapy for Leber Hereditary Optic Neuropathy: low- and medium-dose visual results. Ophthalmology 124(11):1621\u20131634. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.016","journal-title":"Ophthalmology"},{"issue":"1","key":"6776_CR17","doi-asserted-by":"publisher","first-page":"19578","DOI":"10.1038\/s41598-021-98360-7","volume":"11","author":"GV Klink","year":"2021","unstructured":"Klink GV, O\u2019Keefe H, Gogna A, Bazykin GA, Elson JL (2021) A broad comparative genomics approach to understanding the pathogenicity of Complex I mutations. Sci Rep 11(1):19578. https:\/\/doi.org\/10.1038\/s41598-021-98360-7","journal-title":"Sci Rep"},{"issue":"573","key":"6776_CR18","doi-asserted-by":"publisher","first-page":"eaaz7423","DOI":"10.1126\/scitranslmed.aaz7423","volume":"12","author":"P Yu-Wai-Man","year":"2020","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V et al (2020) Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med 12(573):eaaz7423. https:\/\/doi.org\/10.1126\/scitranslmed.aaz7423","journal-title":"Sci Transl Med"},{"issue":"2","key":"6776_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40259-021-00468-9","volume":"35","author":"C Vignal-Clermont","year":"2021","unstructured":"Vignal-Clermont C, Girmens JF, Audo I, Said SM, Errera MH, Plaine L, O\u2019Shaughnessy D, Taiel M, Sahel JA (2021) Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL study. BioDrugs: clinical immunotherapeutics,biopharmaceuticals and gene therapy. 35(2):201\u2013214. https:\/\/doi.org\/10.1007\/s40259-021-00468-9","journal-title":"BioDrugs: Clin Immunother Biopharm Gene Ther"},{"issue":"6","key":"6776_CR20","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1523\/JNEUROSCI.23-06-02284.2003","volume":"23","author":"Y Yin","year":"2003","unstructured":"Yin Y, Cui Q, Li Y, Irwin N, Fischer D, Harvey AR, Benowitz LI (2003) Macrophage-derived factors stimulate optic nerve regeneration. J Neuroscience: Official J Soc Neurosci 23(6):2284\u20132293. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-06-02284.2003","journal-title":"J Neuroscience: Official J Soc Neurosci"},{"key":"6776_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3389\/fnmol.2017.00333","volume":"10","author":"J Ariazi","year":"2017","unstructured":"Ariazi J, Benowitz A, De Biasi V et al (2017) Tunneling nanotubes and gap junctions-their role in Long-Range Intercellular Communication during Development, Health, and Disease conditions. Front Mol Neurosci 10:333. https:\/\/doi.org\/10.3389\/fnmol.2017.00333","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"6776_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3233\/RNN-180880","volume":"36","author":"BA Sabel","year":"2018","unstructured":"Sabel BA, Flammer J, Merabet LB (2018) Residual vision activation and the brain-eye-vascular triad: Dysregulation, plasticity and restoration in low vision and blindness - a review. Restor Neurol Neurosci 36(6):767\u2013791. https:\/\/doi.org\/10.3233\/RNN-180880","journal-title":"Restor Neurol Neurosci"},{"issue":"6","key":"6776_CR23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.5301\/ejo.5000154","volume":"22","author":"P Barboni","year":"2012","unstructured":"Barboni P, Savini G, Feuer WJ et al (2012) Retinal nerve fiber layer thickness variability in Leber hereditary optic neuropathy carriers. Eur J Ophthalmol 22(6):985\u2013991. https:\/\/doi.org\/10.5301\/ejo.5000154","journal-title":"Eur J Ophthalmol"},{"key":"6776_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1471-2415-14-105","volume":"14","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Huang H, Wei S, Gong Y, Li H, Dai Y, Zhao S, Wang Y, Yan H (2014) Characterization of macular thickness changes in Leber\u2019s hereditary optic neuropathy by optical coherence tomography. BMC Ophthalmol 14:105. https:\/\/doi.org\/10.1186\/1471-2415-14-105","journal-title":"BMC Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06776-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06776-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06776-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:16:00Z","timestamp":1755846960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06776-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6776"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06776-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Shiyan Taihe Hospital, Hubei University of Medicine (approval no.:201919) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}